SPRY

ARS Pharmaceuticals, Inc

SPRY, USA

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

https://ars-pharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SPRY
stock
SPRY

Institution Moves: How geopolitical tensions affect SPRY stock - Weekly Stock Summary & Fast Moving Stock Watchlists moha.gov.vn

Read more →
SPRY
stock
SPRY

Discipline and Rules-Based Execution in SPRY Response news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$28.6667

Analyst Picks

Strong Buy

5

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.85

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-34.64 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.72 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-145.36 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.52

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 80.94% of the total shares of ARS Pharmaceuticals, Inc

1.

RA Capital Management, LLC

(10.99%)

since

2025/06/30

2.

Deerfield Management Co

(9.84%)

since

2025/06/30

3.

Orbimed Advisors, LLC

(8.3869%)

since

2025/06/30

4.

BlackRock Inc

(4.476%)

since

2025/06/30

5.

SR ONE CAPITAL MANAGEMENT, LP

(4.0606%)

since

2025/06/30

6.

AllianceBernstein L.P.

(3.8712%)

since

2025/06/30

7.

Vanguard Group Inc

(3.3014%)

since

2025/06/30

8.

Citadel Advisors Llc

(2.2688%)

since

2025/06/30

9.

State Street Corp

(2.2206%)

since

2025/06/30

10.

Franklin Resources Inc

(1.8505%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(1.7758%)

since

2025/07/31

12.

Adage Capital Partners Gp LLC

(1.7485%)

since

2025/06/30

13.

Southpoint Capital Advisors LP

(1.7294%)

since

2025/06/30

14.

FMR Inc

(1.5856%)

since

2025/06/30

15.

Aberdeen Group PLC

(1.5204%)

since

2025/06/30

16.

Goldman Sachs Group Inc

(1.4817%)

since

2025/06/30

17.

Wellington Management Company LLP

(1.4502%)

since

2025/06/30

18.

Octagon Capital Advisors LP

(1.366%)

since

2025/06/30

19.

Geode Capital Management, LLC

(1.3583%)

since

2025/06/30

20.

iShares Russell 2000 ETF

(1.3429%)

since

2025/08/31

21.

MPM Oncology Impact Management LP

(1.3189%)

since

2025/06/30

22.

Rubric Capital Management LP

(1.3103%)

since

2025/06/30

23.

AB Small Cap Growth A

(1.062%)

since

2025/07/31

24.

Franklin Biotechnology Discv A(acc)USD

(1.0595%)

since

2025/08/31

25.

SPDR® S&P Biotech ETF

(0.9967%)

since

2025/08/31

26.

abrdn Healthcare Investors

(0.9845%)

since

2025/08/31

27.

Fidelity Select Biotechnology

(0.9135%)

since

2025/07/31

28.

MEDICAL BioHealth EUR Acc

(0.8239%)

since

2025/06/30

29.

AB Discovery Growth A

(0.7501%)

since

2025/07/31

30.

abrdn Healthcare Opportunities

(0.6783%)

since

2025/07/31

31.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5761%)

since

2025/07/31

32.

Franklin Biotechnology Discovery A

(0.5682%)

since

2025/07/31

33.

Fidelity Small Cap Index

(0.5571%)

since

2025/06/30

34.

APO Medical Opportunities R

(0.509%)

since

2025/07/31

35.

iShares Russell 2000 Growth ETF

(0.4903%)

since

2025/08/31

37.

abrdn Life Sciences Investors

(0.3804%)

since

2025/08/31

38.

iShares Biotechnology ETF

(0.3317%)

since

2025/08/31

39.

EQ/AB Small Cap Growth IB

(0.3024%)

since

2025/07/31

40.

Lisanti Small Cap Growth Composite

(0.2949%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.52

EPS Estimate

-0.4581

EPS Difference

-0.0619

Surprise Percent

-13.5123%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.